Authors
Latest:
Bone Marrow Biopsy Simulation Training for FellowsA bone marrow aspirate and biopsy is the single most common procedure that hematologists and oncologists carry out day in and day out throughout their career.
Latest:
Dr. Bianchi on Diagnostic Factors for AL AmyloidosisGiada Bianchi, MD, discusses diagnostic factors for light chain amyloidosis.
Latest:
Dr. Agnelli Discusses Apixaban for Venous ThromboembolismGiancarlo Agnelli, MD, University of Perugia, Perugia, Italy, discusses the results of a study comparing the efficacy and safety of two doses of apixaban, an oral factor Xa inhibitor, with placebo for the treatment of venous thromboembolism.
Latest:
Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung CancerGilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.
Latest:
Dr. Lopes Discusses Steroid Side Effects in Lung Cancer ManagementGilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses steroid side effects in lung cancer management.
Latest:
Final Thoughts on Effective Therapy and Financial ToxicityExperts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
Latest:
Dr. Salles on Improving Immune Respone in Follicular LymphomaGilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.
Latest:
Bispecific Antibodies May Revolutionize the Management of B-Cell LymphomaThe safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.
Latest:
CRC Tumor Sidedness Plays an Increasing Role in Clinical PracticePrognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.
Latest:
Emerging Uses for Circulating Tumor Cell TechnologyDetection of circulating tumor cells, which are released from primary or metastatic lesions into the bloodstream and are the “seeds” for distant metastatic lesions, has been of interest in cancer research and treatment because these cells can potentially provide information on cancer detection, prognosis, and likelihood of treatment response with minimally invasive methods.
Latest:
Tailoring Therapy for HR-Positive Breast CancerExperts discuss the most effective ways to use new targeted therapies for patients with advanced hormone receptor-positive breast cancer in an OncLive Peer Exchange® panel.
Latest:
FDA Approval Sought for Frontline Cabozantinib/Nivolumab Combo in Advanced RCCA supplemental new drug application has been submitted to the FDA for the combination of cabozantinib and nivolumab as a treatment for patients with advanced renal cell carcinoma.
Latest:
Dr. D’Amato on Optimizing Treatment for Patients With Desmoid TumorsGina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.
Latest:
RECORD-3 Molecular Analysis Characterizes Poor-Risk Patients With mRCCTo best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.
Latest:
Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLCGiorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.
Latest:
Dr. Scagliotti on Preventive Measures to Reduce COVID-19 Risk in OncologyGiorgio Vittorio Scagliotti, MD, PhD, discusses the precautionary measures implemented in clinical practice to protect patients with cancer from COVID-19.
Latest:
Dr. Di Costanzo on the Effectiveness of Sorafenib in HCCGiovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).
Latest:
The Ratings GameThe rise of social networking websites that encourage patients to rate their physicians and discuss their experiences has some practitioners worried about the damage a malicious review could do to their practice.
Latest:
Dr. Grignani on the Patient Population of Trabectedin for SarcomaGiovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.
Latest:
Dr. Putcha on the Utility of Blood-Based Assays in CRCGirish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.
Latest:
Patient Resistance to Swallowing Exercises After Multimodality TherapyGiselle Carnaby, PhD, professor, ASHA fellow, Communication Sciences and Disorders, University of Central Florida, discusses rehabilitation of swallowing after multimodality therapy in patients with head and neck cancer, and why they may be resistant to it.
Latest:
Dr. Banna on the Potential for CAR T-Cell Therapy in Lung CancerGiuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.
Latest:
Dr Curigliano on the Implications of T-DXd in HR+, HER2-Low and -Ultralow Breast CancerGiuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.
